As a consequence of the improvement in insulin sensitivity, PPARγ activation by thiazolidinediones decreases glycated hemoglobin (HbA1c) and lowers the glucose and insulin levels in patients with type 2 diabetes [63]. This evidence concerns the gene PPARG and type 2 diabetes mellitus.